Functional, signaling competent BCRs deliver critical prosurvival signals, termed tonic signals, which maintain and promote both non-transformed and neoplastic B-cell survival. [1] [2] [3] During B-cell development, iterative recombination of heavy and light chain immunoglobulin (Ig) loci culminates in the generation of a B-cell receptor (BCR) repertoire with diverse antigen-binding potential. 1 This nonspecific recombination raises the possibility of generating autoreactive, pathological clones. Therefore, during development, mechanisms are in place that trigger deletion of autoreactive B-cell clones after BCR engagement. [4] [5] [6] Deletion appears driven by three distinct mechanisms: low affinity interaction with soluble antigen preferentially invokes either cellular anergy or re-initiation of Ig locus recombination, termed receptor editing. 7 In contrast, high affinity interactions with membrane-bound auto-antigen predisposes toward programmed cell death. 4, 6 Because BCR ligation via monoclonal antibodies (mAbs) drives apoptosis in normal and neoplastic B cells, the unique BCR expressed by each tumor constitutes an attractive therapeutic target. [8] [9] [10] Accordingly, anti-idiotypic mAbs have proved successful in limited-scale clinical trials. 11 Although such labor-intensive, patient-specific therapies remain impractical, a deeper understanding of events leading to BCR-induced apoptosis may engender alternative therapies. For example, small molecule inhibitors have begun to realize the potential of targeting pro-survival BCR signaling. 12 Although responsive to such therapy, malignant cells often also remain sensitive toward BCR-directed mAb killing. Therefore, combinational inhibition of pro-survival BCR signals alongside pharmacological activation of BCRmediated cell death pathways may prove therapeutically fruitful. However, at present, the precise molecular events that drive BCR-induced apoptosis in B-cell neoplasms remains poorly defined. 10 In mammalian cells, apoptosis occurs via the extrinsic and intrinsic pathways, culminating in effector caspase activation, degradation of key intracellular components, and ultimately cell death. 13 Extrinsic pathway activation follows ligation of members of the TNF-R family, such as CD95/Fas, leading to caspase-8 activation. 13 In contrast, the intrinsic pathway drives caspase-9 and then effector caspase activation via apoptogenic factors released following mitochondrial outer membrane permeablization (MOMP).
14 This process is subjected to complex regulation by the Bcl-2 protein family. 15 It is generally accepted that MOMP is driven through oligomerization of pro-apoptotic Bax-like Bcl-2 family members (Bax, Bak, and possibly Bok) at the outer mitochondrial membrane. 16, 17 In healthy cells, Bax-like proteins are actively repressed by prosurvival Bcl-2 family members (Bcl-2, Bcl-X, Bcl-w, Mcl-1, and Bfl-1). Following cellular stresses, the proapoptotic BH3-only proteins (Bim, Bid, Puma, Noxa, Bik, Bmf, Hrk, and Bad) de-repress Bax-like proteins, 18, 19 thereby initiating apoptosis. Both intrinsic and extrinsic apoptosis have profound roles in B-cell biology via regulation of cellular homeostasis and tumor suppression. 20, 21 Indeed, mice lacking Bim (or overexpressing Bcl-2) exhibit lymphocyte hyperplasia and antibody-mediated autoimmune pathology. 22, 23 However, more subtle dysregulation of the lymphocyte compartment is also evident upon loss of Puma, Bmf, or Noxa. [24] [25] [26] [27] [28] [29] Furthermore, combined loss of Bim alongside other BH3-only proteins (e.g. Bim and Puma) causes more severe defects than loss of Bim alone. 24, 30 Such observations indicate that Bim represents the major, but not the sole, apoptotic regulator of B-cell homeostasis.
Accordingly, BCR-signaling-induced cell death appears to engage intrinsic apoptosis, 8, 9, 31 predominantly via transcriptional upregulation and alternate splicing of Bim. 32, 33 However, because genetic loss of Bim fails to deliver complete resistance toward BCR-induced apoptosis, roles for additional BH3-only proteins are implied. 10 In this investigation, we characterized the involvement of other BH3-only proteins and assessed their relative contribution toward BCR-induced cell death. We report that, in addition to Bim, BCR signaling results in the upregulation of both Bik and Noxa, which perform key sensitizing roles in apoptosis. Furthermore, we demonstrate for the first time that concomitant loss of Bim and Noxa, and to a lesser extent Bim and Bik, generates greater resistance against BCR-induced cell death in B lymphomas than loss of Bim alone.
Results
Both in vivo and in vitro BCR stimulation induces intrinsic/mitochondrial apoptosis via a Syk/MEK-dependent pathway. Although Bim represents the major driver of BCR-induced cell death in non-transformed B cells, 10, 32, 33 loss of Bim does not yield equivalent resistance to that produced by Bcl-2 overexpression, 10 indicating roles for additional BH3-only proteins. To identify these additional drivers and expand these studies to neoplastic B cells, we analyzed the sensitivity of a series of BH3-only protein deficient Eμ-Myc lymphomas toward BCR stimulation.
To verify that Eμ-Myc lymphomas were sensitive to killing by anti-BCR mAbs through apoptosis, IgM + Eμ-Myc lymphomas were transduced with a FLAG-tagged hBcl-2 construct (Supplementary Figures 1A and B) and inoculated into SCID/NOD/FcγR − / − mice. These mice lack T and B cells, have reduced NK activity, and lack the activatory FcγR required for mAb deletion through immune-effector cells. 34 This approach allowed the contribution of apoptosis to the antitumor response following BCR stimulation to be assessed in the absence of other potential effector systems. Mice receiving mock-transduced Eμ-Myc lymphoma cell lines demonstrated significant therapeutic responses toward anti-IgM mAb, increasing median survival from 16 to 25 days in comparison with non-treated animals. However, Bcl-2 overexpression completely abrogated this response (Figure 1a) . Interestingly, Bcl-2-transduced lymphomas exhibited a reduced rate of growth in vivo, as previously described. 35 Such differences may result from enhanced immunogenicity or through Bcl-2-mediated constraint of cell-cycle progression. 35, 36 Similarly, in vitro Bcl-2 overexpression conferred almost complete resistance toward BCR signaling induced cell killing in all Eμ-Myc lymphoma cell lines examined, whereas transduction with the empty vector had little effect (Figure 1b) Figure 1C) . Taken together, these data implicate the intrinsic apoptotic pathway as the key driver of anti-IgM therapy in this system. Intrinsic/mitochondrial apoptosis drives both caspasedependent and -independent cell death following Bax/Bakdependent MOMP. 14, [38] [39] [40] In order to dissect the BCR-induced apoptotic pathway, the effect of the pan-caspase inhibitor qVD-OPH was assessed. Anti-IgM stimulation induced a robust reduction in mitochondrial membrane potential (Ψm) (Figure 1c ). This drop in Ψm (ΔΨm) was completely abrogated by overexpression of Bcl-2, yet appeared unaffected by qVD-OPH pre-treatment. Contrastingly, anti-IgM-induced apoptotic morphology and biochemical markers (e.g. Annexin V staining) were almost entirely abrogated by either qVD-OPH pretreatment or overexpression of Bcl-2 ( Figure 1c) .
BCR stimulation induced substantial PARP cleavage and accumulation of cleavage fragments (indicative of activation) of caspases-9, -2, -3 (Figure 1d ), -6, and -7 ( Supplementary  Figure 2) . At rest, significant levels of PARP cleavage were evident in untreated Eμ-Myc lymphoma cells (Figure 1d ), likely attributable to ongoing Myc-driven oncogene-induced cell death. 41 Considered alongside the finding that Bcl-2 overexpression protects against BCR stimulation-induced cell death and ΔΨm (Figure 1b ), these observations imply that antiIgM antibody-induced cell death induces caspase-independent ΔΨm prior to the generation of a caspase-driven execution phase, a hallmark of intrinsic/mitochondrial apoptosis.
In order to confirm a requirement for BCR signaling in antiIgM-induced apoptosis, the impact of inhibitors of BCRactivated kinases were examined. BCR stimulation of Eμ-Myc lymphoma cell lines induced rapid and robust phosphorylation of Syk, ERK, Akt, JNK, and p38 but had little impact upon c-Myc expression (Figures 2a and b , Supplementary Figures 3 and 4 , and data not shown). Accordingly, the Syk-inhibitor R406 and the MEK1/2 inhibitor PD0325901 significantly reduced BCR-induced ERK phosphorylation (Figures 2b and c) . Furthermore, R406-mediated Syk inhibition correlated with the inhibition of Syk autophosphorylation at Tyr 525 , whereas the Src family PTKdependent phosphorylation of Tyr 352 remained unaffected. Intriguingly, inhibition of ERK phosphorylation correlated with reduced apoptosis after BCR stimulation (Figure 2d ). In contrast, LY294002-mediated PI3K inhibition had little impact ( Supplementary Figures 3A and B) . These observations imply that some but not all BCR-inducible kinases are responsible for anti-IgM antibody-induced apoptosis and highlight a Syk/MEK/ERK-dependent apoptotic mechanism.
Interestingly, the inhibitory effect of PD0325901 upon BCRinduced cell death was not shared between lymphoma cells and non-transformed B cells (Supplementary Figure 5A) . Therefore, Eμ-Myc lymphomas appear to exhibit differences in BCR-induced signaling networks in comparison with their nonneoplastic counterparts.
BCR signaling upregulates multiple pro-apoptotic members of the Bcl-2 family. Because the Bcl-2 family represent central regulators of intrinsic apoptosis, 18 the impact of BCR stimulation upon expression of the Bcl-2 family was assessed by qPCR and western blotting. Of the BH3-only proteins, only Hrk transcripts could not reliably be detected in Eμ-Myc lymphoma cells (data not shown) consistent with previous reports that Hrk is not expressed, or required for apoptosis, in murine lymphoid cells. 42 Anti-IgM stimulation significantly enhanced Bim, Bik, and Noxa transcript levels in all Eμ-Myc lymphoma cell lines examined (Figure 3a) , whereas little variation was evident in other Bcl-2 family members (Supplementary Figure 6B and data not shown). To examine the generality of these effects, the impact of BCR stimulation upon Bim, Bik, and Noxa transcript expression was examined in murine B-lymphocytes and in human lymphoma cell lines (Ramos and Daudi) ( Supplementary Figures 7 and 8 ). All models exhibited dose-dependent anti-IgM-induced cell death and, in the case of Ramos, this was abrogated upon Bcl-2 overexpression (Supplementary Figure 8B) . The pattern of BCR-induced Bim, Bik, and Noxa transcriptional upregulation was conserved in all models, albeit with varying magnitude and kinetics. At the protein level, BCR stimulation imparted significant increases in the levels of both Bim EL and Bim L isoforms, congruent with decreased Bcl-2 ( Figure 3b ) and Mcl-1 in Eμ-Myc lymphoma cell lines (Supplementary Figure 6C ) and normal B-lymphocytes (Supplementary Figure 7) , consistent with previous studies. 10 Presumably, such BCR-induced decreases in Bcl-2 expression were overcome by ectopic expression of the hBcl-2 Tg, because pMIH Bcl-2 bearing lymphomas appeared completely resistant to BCR-induced apoptosis both in vitro and in vivo (Figures 1a and b) . In contrast, BCR-induced Bim S upregulation was largely undetectable. Because suitable antibodies to detect murine Bik and Noxa were unavailable, the impact of anti-IgM stimulation upon Bik, Bim, and Noxa protein levels was assessed in the human Burkitt's lymphoma cell line Ramos. Significant upregulation of Bim, Bik, and Noxa was observed following BCR stimulation in Ramos cells (Supplementary Figure 8C) . However, Noxa upregulation at the protein level was evident only at later time points, and did not correlate with increased Noxa transcript levels (Supplementary Figure 8C and data not shown).
In Eμ-Myc lymphoma cells, increased Bim expression correlated with enhanced co-immunoprecipitation with pro-survival Bcl-2 family members following anti-IgM stimulation, indicative of enhanced pro-survival neutralization (Figure 3c ). Consistent with their inhibitory effect upon BCRinduced apoptosis, both R406 and PD0325901 blocked BCR stimulation-induced increases in Bim transcripts, while PD0325901 also blocked increases of Bim protein levels (Figures 3d and e) . We were unable to assess the impact of R406 on BCR-induced Bim protein upregulation because R406-treated cells exhibited high levels of death after 24 h. In contrast, neither R406 nor PD0325901 appeared able to fully block Bik or Noxa transcript upregulation, although augmentation of the kinetics of Bik upregulation was apparent (Supplementary Figure 6A) . These data implicate Bim as the major driver of BCR-induced killing of lymphoma cells. Accordingly, Bim − / − Eμ-Myc lymphoma cell lines exhibited extensive resistance toward BCR-induced cell death (Figure 3f ). Interestingly, PD0325901 failed to further enhance resistance of Bim − / − Eμ-Myc lymphoma cell lines toward BCR-induced apoptosis (Supplementary Figure 5B) . Thus, the inhibitory effect of PD0325901 is restricted to inhibition of MEK-dependent Bim upregulation following BCR ligation. However, because the loss of Bim failed to yield resistance equivalent to that produced upon Bcl-2 overexpression, a role for additional BH3-only proteins downstream of MEKindependent BCR signaling was indicated.
Genetic loss of Noxa or Bik renders Eμ-Myc lymphoma cell lines partially resistant toward anti-IgM-induced cell death. Because upregulation of Bik and Noxa transcripts were evident following BCR stimulation, the impact of genetic loss of either Bik or Noxa upon BCR-induced apoptosis was assessed. Bik-or Noxa-deficient Eμ-Myc lymphomas, described previously, 43 demonstrated a slight but significant reduction in the extent of cell death induced upon anti-IgM antibody treatment (Figures 4a and b) . This resistance was evident at all concentrations of anti-IgM antibody, in all cell lines analyzed, and corresponded to a decreased magnitude of effect in both Bik − / − and Noxa − / − Eμ-Myc lymphomas, and an E D 50 shift in Noxa − / − Eμ-Myc lymphomas (Supplementary Figure 9A) . Figure 1b and assessed for cell viability by Annexin V/PI staining followed by flow cytometry. *Po0.05 by two-way ANOVA statistical analysis. Data represent the average of three different lymphoma cell lines Concomitant loss of Bim and Noxa enhances resistance to BCR stimulation-induced apoptosis comparable with overexpression of Bcl-2. Retroviral shRNA-mediated Bim RNAi was utilized to generate lymphomas deficient in both Bim and Noxa, or Bim and Bik. Typically, Bim knockdown was 75% or greater across all genotypes and Bik and Noxa transcript upregulation was maintained following BCR stimulation (Figure 5a and data not shown). As anticipated, Bim knockdown imparted extensive resistance toward BCR-induced apoptosis in WT Eμ-Myc lymphomas, whereas empty vector controls were comparable with non-transduced cell lines (Figure 5b ). Consistent with a role in BCR-induced apoptosis, Bim knockdown in both Bik − / − and Noxa
Eμ-Myc lymphomas yielded greater resistance than Bim knockdown alone (Figure 5c ). Although the effect of combined loss of Bim and Bik was slight, a significant trend toward enhanced resistance was evident at all concentrations of anti-IgM antibody (Figure 5c ). In contrast, Bim knockdown Noxa − / − Eμ-Myc lymphomas exhibited substantial resistance, yielding a level of resistance toward BCR-induced cell death comparable with that produced by Bcl-2 overexpression (Figure 5c ).
Discussion
Data presented here demonstrate that upregulation of Bim, Noxa, and Bik drives maximal killing during BCR-induced apoptosis in Eμ-Myc lymphoma cells. In agreement with previous studies, we identify that caspase-independent initialization of MOMP precedes a caspase-activation cascade that directly initiates cellular execution. 8, 44, 45 Taken alongside data demonstrating that Bcl-2 overexpression causes complete resistance to BCR-induced cell death (Figure 1b and 10 ), such data directly link the BCR to the intrinsic/mitochondrial pathway of apoptosis. Following MOMP, we observed substantial activation of initiator caspases-2 and -9 and effector caspases-3, -6, and -7. The exact identity of the key BCRinduced initiator caspase remains unclear, 8, 9, 44 largely from an inability to rule out the possibility that BCR-induced caspase-2 cleavage (indicative of its activation) results directly from positive feedback via effector caspases. 8, 44 Furthermore, observations that mice deficient in caspase-2, caspase-9, or mice possessing a caspase-2 − / − ; caspase-9 − / − hematopoietic system do not exhibit autoimmune pathology indicates that deletion of autoreactive B-cells (by BCR-induced apoptosis) occurs normally in their absence. 46, 47 Therefore, it is likely that either the caspase activation pathway downstream of the BCR exhibits redundancy or that caspase-independent mechanisms suffice to cause cell death.
In agreement with previous studies, our data identify Bim as the major driver of BCR-induced apoptosis, 10, 32, 33 reflected in the widespread dysregulation of B-lymphocyte homeostasis in Bim − / − mice. 10, 22 Indeed, BCR stimulation-driven Bim upregulation has been attributed to a combination of transcriptional upregulation and isoform skewing, via JNK-dependent alternative splicing and Bim EL protein degradation, toward expression of the more highly pro-apoptotic Bim L isoform. 32, 33 However, recent studies demonstrate that such alternative Figure 4 Genetic loss of Bim, Bik, or Noxa significantly impairs BCR-induced killing of Eμ-Myc lymphoma cells. Eμ-Myc lymphoma cell lines derived from animals deficient in Bim (n = 3) (a-d), Bik (n = 3) (a), Noxa (n = 5) (b), Puma (n = 5) (c), or Bid (n = 2) (d) were cultured as in Figure 1 and sensitivity toward pAb anti-IgM F(ab) 2 was assessed in comparison with WT Eμ-Myc lymphoma cell lines (n = 5) by Annexin V/PI staining followed by flow cytometry. *Po0.05 as assessed by two-way ANOVA statistical analyses. n.s = not significantly different. n denotes the number of different Eμ-Myc lymphoma cell lines used per genotype splicing mechanisms are largely dispensable for Bim function. 48 In Eμ-Myc lymphomas, BCR-mediated Bim upregulation occurred primarily via a Syk/MEK/ERK-dependent transcriptional mechanism, whereas inhibition of JNK had little effect (data not shown). Although well documented, the exact nature of ERK-mediated regulation of Bim remains unclear. It was initially proposed that ERK functions as a prosurvival, posttranslational modifier of Bim via direct phosphorylation of Ser 69 resulting in polyubiquitination, proteasomal targeting, and reduced Bim EL expression. [49] [50] [51] However, mice exhibiting mutations within the Bim EL DEF2 domain (which abrogate ERK:Bim docking) demonstrate normal hematopoietic homeostasis and apoptotic sensitivity. 48 These studies demonstrate that although ERKmediated Bim EL degradation is evident in vitro following certain apoptotic stimuli, it is dispensable for Bim function in vivo. Alternatively, it is suggested that ERK may regulate Bim transcriptionally by a mechanism centered upon the 3' UTR of Bim mRNA in sympathetic neurons and may directly influence miRNA-mediated control of Bim expression in nonsmall cell lung carcinomas. 52, 53 Regardless of the exact mechanism, ERK is largely associated with a negative regulatory impact upon Bim expression. Such a role is most likely reflected in our observation that MEK inhibition in both normal and preneoplastic Myc-Tg B-lymphocytes exacerbated BCR-induced cell death (Supplementary Figure 5A) . Therefore, it appears BCR-mediated Bim transactivation occurs via a lymphomaspecific, ERK-dependent mechanism in Eμ-Myc lymphoma cells. Indeed, altered MAPK signaling kinetics have been observed in malignant lymphoma cells in comparison with their non-transformed counterparts. 54 Whether these observed differences contribute toward lymphoma-specific cellular outcomes remains a topic of ongoing research.
Our data therefore imply that pharmacological activation of ERK signaling, akin to that produced upon BCR-induced cell death, may prove a successful combination therapy alongside PI3K inhibitors, such as Idelalisib, because PI3K inhibition failed to influence the extent of BCR-induced cell killing.
Although we demonstrated that Bim has a major role downstream of the BCR, its genetic loss did not yield resistance equivalent to that produced upon Bcl-2 overexpression, as − / − (n = 3) (c left panel), or Noxa − / − (n = 3) (c center panel) backgrounds were assessed for sensitivity to BCR-induced cell death by Annexin V/PI staining followed by flow cytometry after 24 h. *Po0.05 by two-way ANOVA statistical analysis (b, c left and center panels) or by unpaired Student's T-test statistical analysis (c right panel). n denotes the number of different Eμ-Myc lymphoma cell lines used per genotype described previously in an alternate system. 10 Therefore, BCR engagement likely activates additional BH3-only proteins to achieve maximal apoptosis. Our data suggest minor but significant roles for both Noxa and Bik in BCR-induced apoptosis. Although a role for Bik downstream of the BCR has long been suspected but poorly defined, 55 the implication of Noxa represents a novel finding. However, in recent years, a putative co-operative relationship between Bim and Noxa has become apparent downstream of antigen receptors. Indeed, transcriptional upregulation of Noxa has been observed following the activation of both B-and T-cell antigen receptors and a co-operative role in T-cell receptor (TCR) stimulationinduced apoptosis has been demonstrated alongside Bim and Puma. 26, 27, 30, 56 Furthermore, Noxa appears to sensitize lymphocytes with low-affinity antigen receptors toward cell death during the germinal center reaction. 26 Such observations, along with our own, imply the existence of a conserved pathway linking antigen receptor activation to transcriptional regulation of Bim and Noxa. Noxa transcript regulation is most often associated with p53 transactivation, 57, 58 however, additional p53-independent processes involving HIF1α 59 and PKC 60 have also been documented among others. It is possible that BCRinduced Noxa transactivation occurs via a PKC-dependent mechanism, because although Syk activity was dispensable for Noxa transactivation, Bruton's Tyr Kinase (Btk) activity may be sufficient to drive PLCγ2-mediated PKC activation. 61 Interestingly, the combined loss of Noxa and Bim (but not combined loss of Bik and Bim) yielded resistance to BCR-induced apoptosis statistically identical to that produced with hBcl-2 overexpression. These data implicate Noxa as a key inducer of MOMP (in addition to Bim) following BCR ligation, consistent with its purported direct activator function. 62 However, such activity remains disputed and would not explain the apparently normal phenotype of Noxa − / − mice. 57 A more likely situation is reflected in the ability of Noxa to target Mcl-1 for proteasomal degradation 63 resulting in MOMP via a reduction in pro-survival protein inhibition of Bax/Bak oligomerization. Indeed, observations of BCR-induced Mcl-1 degradation in Eμ-Myc lymphoma cell lines appear to corroborate this (Supplementary Figure 6C) . However, whether Mcl-1 degradation alone, without BH3-only protein-mediated activation of Bax/ Bak, is capable of inducing MOMP remains debatable. Whereas elevated levels of Noxa transcripts were sustained following BCR stimulation in Eμ-Myc lymphomas, the human lymphoma cell line Daudi, and normal murine B-lymphocytes, a shorter duration of response was evident in Ramos cells (Supplementary Figures 8A and B) . However, in Ramos, Noxa protein upregulation at the protein level was evident at later time points, which did not correlate with increased transcript levels (Supplementary Figure 8C and data not shown). Therefore, both transcriptional and nontranscriptional mechanisms may exist linking BCR stimulation to Noxa upregulation.
Our data suggest a lesser role for Bik downstream of the BCR. Although BCR-induced Bik upregulation has been previously observed, 55 studies to abrogate Bik expression in lymphoma cells have been lacking. Studies in Bik − / − mice demonstrated that Bik appears dispensable for apoptotic responses to many cell death stimuli in non-transformed B-lymphocytes, including BCR stimulation. 64, 65 However, in recent years, Bik has been implicated in B-cell homeostatic control in both malignant and non-neoplastic B-lymphocytes, via its involvement in TGF-β-induced cell death. 66 In a malignant setting, we and others demonstrate conserved upregulation of Bik transcripts downstream of BCR stimulation in multiple models (Figure 3a and Supplementary Figures 7  and 8) , 55 and here for the first time, we show a reduction in BCR-induced killing of Eμ-Myc lymphoma cells following loss of Bik. It is therefore likely that BCR-signaling-induced cell death has different BH3-only requirements, or at least different kinetics of BH3-only induction, in alternate cellular contexts. In support of this, we demonstrate a delayed upregulation of Bik transcripts in normal lymphocytes, in comparison with malignant B-cell models (Figure 3 and Supplementary  Figures 7 and 8) . Consequently, a functional role for Bik downstream of the BCR may be restricted to malignant lymphocytes, explaining the apparently normal sensitivity of Bik − / − B cells toward BCR stimulation. 65 It is conceivable that differences in BCR-induced signaling pathways between normal and neoplastic B-lymphocytes may invoke alternate cell death pathways downstream of the BCR. 54 Although our data suggest that Bik alone is unable to drive cell death, it appears to perform a sensitization role downstream of the BCR consistent with its role as a sensitizer BH3-only protein. 67 We therefore propose that although Bim represents the major executioner downstream of the BCR, both Noxa and to a lesser extent Bik perform sensitization roles.
Materials and Methods
Mice. Eμ-Myc Tg mice were described previously. 68 SCID/NOD mice were obtained from the Jackson Laboratory (Bar Harbour, ME, USA) and intercrossed with FcγR Antibodies and inhibitors. Polyclonal goat anti-mouse/human IgM specific F(ab)' 2 (Jackson Immunotech, West Grover, PA, USA) was utilized for in vitro BCR stimulation. Monoclonal rat-anti-mouse IgM (IgG2a: clone Mc39.12) was produced in-house, and utilized in vivo (3 × 125 μg i.v. injections on days 7, 14, and 21 post tumor). Antibodies used for western blot analysis are detailed in the Supplementary methods. qVD-OPH was obtained from MP Biochemicals (Santa Ana, CA, USA). R406 and PD0325901 were obtained from Selleck Chemicals (Houston, TX, USA).
Cell viability assays. Annexin V/propidium iodide (PI) assays were performed as previously described. 69, 70 Briefly, cells were re-suspended at 0.6 × 10 6 cells/ml and subjected to the indicated concentration of antibody/drug for 24 h, harvested and stained in medium with Annexin V FITC (1 μg/ml) and PI (3.6 μg/ml, Sigma) for 15 min and analyzed on a FACScan (BD Biosciences, Oxford, UK) flow cytometer. DiOC 6 /PI staining was performed by addition of DiOC 6 (Life Technologies) to cells at 10 nM 30 min prior to harvesting. Cells were harvested, washed, and resuspended in medium containing PI (3.6 μg/ml) and analyzed by flow cytometry. Stimulus-specific cell death/ Ψm was calculated by 100-((viability/vehicle-treated viability) × 100).
Quantitative PCR. RNA was purified using Purelink RNA-mini kit (Life Technologies) and quality-assessed using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). RNA was converted to cDNA using the Superscript first-strand synthesis kit (Life Technologies) and combined with Taqman gene expression assays (Supplementary methods for assay ID), qPCR supermix UND (Life Technologies), and analyzed using a Bio-Rad CFX96 (Bio-Rad, Hemel-Hempstead, UK). Data were converted to fold change using the 2 -ΔΔcT -normalization method using GAPDH as a reference.
Western blotting and immunoprecipitation. Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5% v/v Triton x-100, 0.5% w/v Deoxycholate, 0.1% SDS, 50 mM NaF, 2 mM NaVO 4 ) and subjected to western blotting using standard techniques. For immunoprecipitation, 1 × 10 8 cells per sample were lysed in CHAPS lysis buffer (20 mM Tris pH 7.4, 142.5 mM KCl, 2 mM CaCl 2 , 1% CHAPS). Five hundred micrograms of protein were adjusted to 500 μl and pre-cleared via addition of 50 μl 50% v/v Protein G Sepharose in CHAPS lysis buffer for 2 h at 4°C. Concurrently, Protein G Sepharose was blocked by incubation with 5% normal Rat serum for 2 h at 4°C. Pre-cleared lysates and blocked beads were subsequently pelleted by centrifugation and the relevant fractions retained. Pre-cleared lysates were then incubated with 50 μl blocked protein G Sepharose and 5% normal rat serum for 2 h at 4°C, after which samples were centrifuged and the beads discarded. Simultaneously, 50 μl blocked protein G Sepharose was incubated with a sufficient amount of antibody to give a final concentration (when applied to lysates) of 2 μg/ml for 2 h at 4°C. Lysates were then centrifuged, the bead pellet discarded, and 50 μl of the antibody bead mixtures added to lysates and mixed overnight at 4°C with agitation. Beads were subsequently pelleted, retained, and washed five times in lysis buffer followed by incubation with reducing 2 × Laemmli buffer and boiled for 5 min. Lysates were then analyzed by SDS-PAGE and western blotting using Tru-Blot HRP-conjugated antibodies (eBioscience, Hatfield, UK) as the secondary reagents.
Generation of ShRNA or Bcl-2 expressing Eμ-Myc lymphoma cells. For generation of Bim knockdown or Bcl-2 overexpressing Eμ-Myc lymphomas, a retroviral spin-infection protocol was used as described previously. 69 Ecotropic ϕnix cells were grown in DMEM supplemented with 10% fetal calf serum, 2 mM Glutamine, 1 mM Pyruvate, 45 units/ml Penicillin, and 45 μg/ml Streptomycin at 37°C, 10% CO 2 . ϕnix cells were incubated with 5 μM Chloroquine for 5 min prior to transfection via Ca 2+ : phosphate precipitation. Retroviral constructs based on murine stem cell virus (MscV) puro IRES/GFP (pMscV.Puro.Ires.GFP) and MscV IRES hygro (pMIH) were utilized containing ShBim and Bcl-2 constructs, respectively. Ten micrograms of pMIH-Bcl-2 or pMscV.Puro.Ires.GFP ShBim (or empty vectors) were diluted alongside 4 μg p.CL-Eco in HEPES-buffered saline followed by addition of CaCl 2 to 120 mM. Mixtures were applied to ϕnix cells and incubated at 37°C, 5% CO 2 for 8 h, before the medium was replaced, left for 48 h and viral supernatants collected. Polybrene was added to viral supernatants at 4 μg/ml and 1.5 ml supernatant added to 6 × 10 5 Eμ-Myc lymphoma cells, before centrifugation at 180 × g, 37°C for 45 min. Cells were then incubated at 37°C, 10% CO 2 for 48 h. Puromycin (1 μg/ml) or Hygromycin (250 μg/ml) was then added for 7 days. The top 5% of GFP-positive transduced cells were then sorted (FACSaria). Bcl-2 overexpression was confirmed by intracellular flow cytometry.
Statistical analysis. Data are expressed as mean ± S.E.M. Statistical significance between two groups was assessed by either paired/un-paired Student's T-test. For experiments involving multiple variables, statistical significance was assessed via two-way ANOVA. Survival was assessed via Mantel-Cox statistical analysis.
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